UBS Group’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-8,513
| Closed | -$4K | – | 8630 |
|
|
2018
Q4 | $4K | Buy |
+8,513
| New | +$5.29K | ﹤0.01% | 7691 |
|
|
2018
Q2 | – | Sell |
-6,516
| Closed | -$16K | – | 8626 |
|
|
2018
Q1 | $16K | Buy |
6,516
+4,878
| +298% | +$12.3K | ﹤0.01% | 6598 |
|
|
2017
Q4 | $4K | Sell |
1,638
-999
| -38% | -$2.76K | ﹤0.01% | 7510 |
|
|
2017
Q3 | $8K | Buy |
2,637
+1,496
| +131% | +$4.8K | ﹤0.01% | 7045 |
|
|
2017
Q2 | $5K | Buy |
1,141
+359
| +46% | +$1.56K | ﹤0.01% | 7177 |
|
|
2017
Q1 | $3K | Sell |
782
-2,184
| -74% | -$6.85K | ﹤0.01% | 7254 |
|
|
2016
Q4 | $6K | Buy |
2,966
+192
| +7% | +$695 | ﹤0.01% | 7200 |
|
|
2016
Q3 | $17K | Sell |
2,774
-2,945
| -51% | -$18.2K | ﹤0.01% | 6455 |
|
|
2016
Q2 | $25K | Buy |
5,719
+5,201
| +1,004% | +$34K | ﹤0.01% | 6136 |
|
|
2016
Q1 | $5K | Sell |
518
-2,475
| -83% | -$49.2K | ﹤0.01% | 7044 |
|
|
2015
Q4 | $88K | Sell |
2,993
-3,497
| -54% | -$106K | ﹤0.01% | 5323 |
|
|
2015
Q3 | $205K | Buy |
6,490
+2,700
| +71% | +$129K | ﹤0.01% | 4624 |
|
|
2015
Q2 | $224K | Sell |
3,790
-320
| -8% | -$22.6K | ﹤0.01% | 4773 |
|
|
2015
Q1 | $439K | Buy |
4,110
+810
| +25% | +$77.2K | ﹤0.01% | 4247 |
|
|
2014
Q4 | $310K | Buy |
+3,300
| New | +$315K | ﹤0.01% | 4630 |
|
UBS Group's PTX Position: Q1 2019 in Review
UBS Group sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 8,513 shares — an estimated $4K sold.
UBS Group first reported a position in PTX in Q4 2014 and held it in 15 quarters. The position peaked at $439K in Q1 2015. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.
- UBS Group reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
- UBS Group sold 8,513 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $4K.
- UBS Group first reported a position in Pernix Therapeutics Holdings, Inc. in Q4 2014 and held it in 15 quarters.
- UBS Group's Pernix Therapeutics Holdings, Inc. position peaked at $439K in Q1 2015.
- 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.
Based on UBS Group's 13F filing for Q1 2019, filed 14 May 2019.